McKesson is a US pharmaceutical and medical-supply distributor headquartered in Irving, Texas, sitting between drug manufacturers and pharmacies, hospitals and clinics.
Is this your business? Add your evidence →
McKesson's Scope 1 and 2 emissions are falling with Deloitte assurance, but its stated Scope 3, about 99% of its footprint, rose 38% from FY2020 to 35.2 Mt in FY2026. It has SBTi-approved near-term targets but no net-zero target, no biodiversity or nature-risk disclosure, and no water target although about 91% of its water is drawn in water-stressed states. It is a liable party at 12 Superfund sites.
McKesson scores 33/100 (Below expectations) on SINK's independent climate assessment, scored from public data only. Fees pay for the review, never the result. Last verified October 2026.
That places McKesson joint 539th of 847 companies scored, and joint 18th of 19 in Healthcare / Pharmaceuticals.
McKesson is tied at the bottom of the healthcare / pharmaceuticals pack.
Among the 19 major healthcare / pharmaceuticals brands we've scored, McKesson is tied =18th of 19, with 1 other.
Its three lowest-scoring questions, and what the evidence didn't show.
Operations are distribution centers and offices under Green Building Standards for water, energy, waste only.
Company claims 72% progress toward near-term target but dominant scope remains well above baseline.
No multi-year trend, reduction target or discharge data.
A score changes when the evidence does. We use new published evidence at the next rescore. Evidence that isn't public can count through an evidence review.
Use this score in tenders
Send the link, or the one-page score sheet. It links back to this page and every source. Free.
Open the score sheet →Add your evidence, £99
Scored low because little is published? Send us your evidence. A person reviews it and your score reflects what you really do. Done within 5 working days.
Evidence review →Go tender-ready, £495 a year
A yearly rescore, a check of up to 25 key suppliers and a score badge for your website (coming soon).
Get in touch →Strongest on Carbon Footprint — Operations and Carbon Footprint — Supply Chain (8/10, 7/10). Weakest on Nature & Biodiversity Impact and Emissions Trajectory (2/10, 3/10).
The 3 companies in the sector scoring nearest above McKesson.
J&J's Scope 1 and 2 emissions fell 38% from 2021, mostly through renewable electricity instruments including unbundled certificates; Scope 1 itself fell only about 3% from 2023 to 2025.
See the breakdown →CVS Health's Scope 1 and 2 emissions are down 43% since 2019 with reasonable assurance, though Scope 1 rose in 2025, and its Scope 3 total of 26.3 Mt has not fallen steadily.
See the breakdown →Cardinal Health reports Scope 1, 2 and 3 emissions with third-party assurance, but its Scope 1 and 2 are only 17% below FY2019 against a 50% cut targeted for FY2030.
See the breakdown →The formula and all 11 sources.
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × Scale11 sources used in this assessment. All publicly available. Each row shows which of the ten questions it informed.
“Direct (Scope 1) GHG emissions 88,219 72,223 68,287”
“Direct (Scope 1) GHG emissions 88,219 72,223 68,287”
“renewable electricity procurement and use, and transportation efficiency improvements.”
“McKesson requires suppliers to align with its greenhouse gas (GHG) reduction targets”
“Reduce absolute scope one and two GHG emissions 50.4% by FY 2032 from a FY 2020 base year”
“Ensure 70% of McKesson suppliers, by spend covering purchased goods and services, will have their own SBTi-approved GHG reduction targets by FY 2027.”
“has received approval by the Science Based Targets initiative (SBTi) for its near-term climate change targets”
“periodically reviews its memberships in trade associations who may engage in policy advocacy”
“Such policies and laws may necessitate reductions in greenhouse gas (“GHG”) emissions”
“Brian S. Tyler, Ph.D. is chief executive officer of McKesson Corporation.”
“a roughly 3 MW solar facility on McKesson’s distribution center in Robbinsville, N.J.”
If you believe a source has been misread or a newer version exists, submit a challenge.
McKesson is a US pharmaceutical and medical-supply distributor headquartered in Irving, Texas, sitting between drug manufacturers and pharmacies, hospitals and clinics. Incorporated in Delaware in 1994, it had about 43,000 employees and $403.4 billion in FY2026 revenue.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Checking a company?
Search free →Asked to prove you're sustainable?
Get your business scored, free →Been scored?
See what's behind your number →Fees pay for the review, never the result.